# EDGAR Filing Document

**Accession Number:** 0001100663
**File Stem:** 0001752724-23-039565
**Filing Date:** 2023-2
**Character Count:** 27860
**Document Hash:** 6158649abc121005a1ae79d6041e74a6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001752724-23-039565.hdr.sgml**: 20230224

**ACCESSION NUMBER**: 0001752724-23-039565

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230224

**DATE AS OF CHANGE**: 20230224

**PERIOD START**: 20230331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** iSHARES TRUST
- **CENTRAL INDEX KEY:** 0001100663
- **IRS NUMBER:** 943351276
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-09729
- **FILM NUMBER:** 23665685

**BUSINESS ADDRESS:**
- **STREET 1:** 400 HOWARD STREET
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94105
- **BUSINESS PHONE:** (415) 670-2000

**MAIL ADDRESS:**
- **STREET 1:** 400 HOWARD STREET
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94105

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ISHARES TRUST
- **DATE OF NAME CHANGE:** 19991213

## Series and Classes Contracts Data

### iShares U.S. Pharmaceuticals ETF (Series ID: S000009417)

| Class ID   | Class Name                       | Ticker Symbol   |
|:---|:---|:---|
| C000025771 | iShares U.S. Pharmaceuticals ETF | IHE             |

## Nport-Ex

# Schedule of Investments (unaudited)

December 31, 2022

iShares® U.S. Pharmaceuticals ETF
(Percentages shown are based on Net Assets)

| Security | Shares | Value |
| --- | --- | --- |
| Common Stocks |  |  |
| Biotechnology- 4.3% |  |  |
| Schedule of Investments |  |  |
| Catalyst Pharmaceuticals, Inc. (a)(b) | 438,225 | $5,350,727 |
| Ironwood Pharmaceuticals, Inc., Class A (a)(b) | 167,804 | 3,121,154 |
| Madrigal Pharmaceuticals, Inc. (a) | 233,893 | 2,897,934 |
|  | 21,267 | 6,172,747 |
| Derivative Financial Instruments Outstanding as of Period End |  |  |

| Security | Shares | Value |
| --- | --- | --- |
| Pharmaceuticals (continued) |  |  |
| Perrigo Co. PLC | 235,972 | $8,044,285 |
| Pfizer, Inc. | 374,975 | 19,213,719 |
| Phibro Animal Health Corp., Class A | 35,728 | 479,113 |
| Plant Therapeutics, Inc. (a) | 58,882 | 1,138,189 |
| Prestige Consumer Healthcare, Inc. (a)(b) | 86,800 | 5,433,680 |
| Reata Pharmaceuticals, Inc., Class A (a)(b) | 48,937 | 1,859,117 |

iShares® U.S. Pharmaceuticals ETF

SCHEDULE OF INVESTMENTS

1

2

(unaudited) (continued)

December 31, 2022

| Vanda Pharmaceuticals, Inc. (a) | 99,412 | 734,655 | Revance Therapeutics, Inc. (a)(b) | 144,194 | 2,661,821 |
| --- | --- | --- | --- | --- | --- |
| Futures Contracts |  | 18,277,217 | Royalty Pharma PLC, Class A | 447,157 | 17,671,645 |
| Pharmaceuticals- 95.5% |  |  | Theravance Biopharma, Inc. (a) | 101,225 | 1,135,745 |
| Aclaris Therapeutics, Inc. (a) | 89,937 | 1,416,508 | Verityx Biosciences, Inc. (a) | 48,626 | 1,594,447 |
| Amphastar Pharmaceuticals, Inc. (a) | 66,070 | 1,851,281 | Viatris, Inc. | 1,728,323 | 19,236,555 |
| Amylyx Pharmaceuticals, Inc. (a) | 69,673 | 2,574,417 | Zoetis, Inc., Class A | 125,383 | 18,374,878 |
| Ademex, Inc. (a) | 84,892 | 2,904,155 | Number of Contracts | Expiration Date | Amount (000) |
| Alex Pharmaceuticals, Inc. (a) | 133,145 | 640,427 | Total Long-Term Investments - 99.8% |  |  |

- •
- •
- •

![img-0.jpeg](img-0.jpeg)

| Asbury, New York | 60,126 | 4,637,518 | (Cost: $406,350,130) | 4 | 03/17/23 | $ | 553 | $ | 1,721 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Bristol-Myers Squibb Co. | 235,690 | 16,957,896 |  |  |  |  |  |  | 418,241,074 |
| Casa Therapeutics, Inc. | 79,292 | 851,596 |  |  |  |  |  |  |  |
| Fair Value Hierarchy as of Period End | 66,012 | 1,949,994 |  |  |  |  |  |  |  |
| Cassava Sciences, Inc. |  |  |  |  |  |  |  |  |  |
| Various inputs are used in determining the fair value of financial instruments. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows: | 59,295 | 1,364,044 |  |  |  |  |  |  |  |
| Concept Therapeutics, Inc. | 167,915 | 3,410,354 |  |  |  |  |  |  |  |
| Level 1 - Unadjusted price quotations in active markets/exchanges for identical assets or liabilities that the Fund has the ability to access: | 59,320 | 1,850,784 |  |  |  |  |  |  |  |
| DICE Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |
| Elanca, Avery & H. Other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar |  |  |  |  |  |  |  |  |  |

# Short-Term Securities

El Lilly & Co. 4,12% 570,383 570,383
Harman, Bessinger, Hollings, Inc. 311,981 3,564,153 Total Short Term Securities 4.2%
Innoviva, Inc. 110,008 1,457,606 (Cost: $17,408,257) 17,414,416
Intra-Opinion Analysis 104,989 8,936,000
Accounting assumptions used in determining the fair value of financial instruments 104,989
Johnson & Johnson 531,657 93,917,209 (Cost: $423,758,387) 435,655,490
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to
Liggett Pharmaceuticals Inc. 28,526 1,879,950 Liabilities in Excess of Other Assets 10,173,919
Unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value in greatest for instruments categorized in Level 2.
Merck & Co., Inc. 271,121 18,985,870
The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is

Nuvation Bio, Inc., Class A$^{M}$ ... 240,550 461,856 **Net Assets - 100.0%** ... \$418,881,672  
 determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable  
 results in the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of the fair value of

The following table summarizes the Fund's financial instruments categorized in the fair value hierarchy. The breakdown of the Fund's financial instruments into major  
 **Affiliates** is disclosed in the Schedule of Investments above.

Investments in issuers considered to be affiliate(s) of the Fund during the period ended December 31, 2022 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

|  | Level 1 | Level 2 | Level 3 | Total |
| --- | --- | --- | --- | --- |
| Investments |  |  |  | Capital |
| Long-Term Investments |  |  |  | Gain |
| Common Stocks | $418,240 | $ - | $ - | $418,240 |
| Short-Term Securities |  |  |  | from |
| Money Market Funds . . . Value at . . . . . Purchases . . . . . Proceeds . . . Net Realized | 17,000 | Value at - Shares Held | - | 17,000 |

| Affiliated Issuer | 03/31/22 | at Cost | from Sale | Gain (Laps) | (Depreciation) | $ | 12/31/22 | at 12/31/22 | Income | £ | £ |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| BlackRock Cash |  |  |  |  |  |  |  |  |  |  |  |
| Derivative Financial Instruments (a) |  |  |  |  |  |  |  |  |  |  |  |
| Funds: International |  |  |  |  |  |  |  |  |  |  |  |
| Agency Shares | $11,796,050 | $5,043,536 (a) | $ - | $2,762 | $1,685 | $16,844,033 | $16,838,981 | $329,186 (a) | $ - |  |  |
| Equity Contracts |  |  |  | $1,721 | $ - | $ - | $ - | $ - | $1,721 |  |  |
| BlackRock Cash |  |  |  |  |  |  |  |  |  |  |  |
| Funds: Treasury, SL |  |  |  |  |  |  |  |  |  |  |  |
| Agency Shares | 400,000 | 170,383 (a) | - | - | - | 570,383 | 570,383 | 9,003 | - (c) |  |  |
| (a) Derivative financial instruments are futures contracts. Futures contracts are valued at the unrealized appreciation (depreciation) on the instrument. |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  | $2,762 | $1,685 | $17,414,416 |  | $338,189 | $ - (c) |  |  |

(a) Represents net amount purchased (sold).

(b) All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

(c) Rounds to less than $1.

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** iShares Trust

- **b. Investment Company Act file number:** 811-09729

- **c. CIK number of Registrant:** 0001100663

- **d. LEI of Registrant:** 5493000860OXIC4B5K91

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 400 Howard Street

  - **City:** San Francisco

  - **State:** CA

  - **Foreign country:** US

  - **Zip / Postal Code:** 94105

  - **Telephone number:** 800-474-2737

**Item A.2. Information about the Series.**

- **a. Name of Series:** iShares U.S. Pharmaceuticals ETF

- **b. EDGAR series identifier (if any):** S000009417

- **c. LEI of Series:** 549300K3OFF3L3ODU217

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2023-03-31

- **b. Date as of which information is reported:** 2022-12-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $435436062.52

**Total Liabilities:** $16554453.53

**Net Assets:** $418881608.99

**Cash Not Reported:** $5480.00

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000025771 | 6.90%                | 3.72%                | -0.16%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $2234321.77              | $24110194.61                               |
| Month 2  | $1408580.71              | $11896154.78                               |
| Month 3  | $10703261.92             | $-11442933.04                              |

### Schedule of Portfolio Investments

| Name                                                                       | Title                                             | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Collegium Pharmaceutical, Inc.                                             | COLLEGIUM PHARMACEUTICAL INC                      | CUSIP: 19459J104<br>LEI: 54930049FXZMTLW8D496 | Long             | EC               | CORP              | US        |     58795 | NS      | $1364044.00   | 0.33%             |  |  |  | No            |                  1 | On Loan: —       |
| Ventyx Biosciences Inc                                                     | VENTYX BIOSCIENCES INC                            | CUSIP: 92332V107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     48626 | NS      | $1594446.54   | 0.38%             |  |  |  | No            |                  1 | On Loan: No      |
| CATALENT, INC.                                                             | CATALENT INC                                      | CUSIP: 148806102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    315407 | NS      | $14196469.07  | 3.39%             |  |  |  | No            |                  1 | On Loan: —       |
| BlackRock Funds III: BlackRock Cash Funds: Treasury; SL Agency Shares      | BLACKROCK CASH FUNDS TREASURY                     | CUSIP: 066922477<br>LEI: N/A                  | Long             | STIV             | RF                | US        |    570383 | NS      | $570383.13    | 0.14%             |  |  |  | No            |                  1 | On Loan: No      |
| LIGAND PHARMACEUTICALS INCORPORATED                                        | LIGAND PHARMACEUTICALS                            | CUSIP: 53220K504<br>LEI: 5493008K7TB0IKP37H79 | Long             | EC               | CORP              | US        |     28128 | NS      | $1878950.40   | 0.45%             |  |  |  | No            |                  1 | On Loan: No      |
| MADRIGAL PHARMACEUTICALS, INC.                                             | MADRIGAL PHARMACEUTICALS INC                      | CUSIP: 558868105<br>LEI: 549300CHIMT2EUSNJB60 | Long             | EC               | CORP              | US        |     21267 | NS      | $6172746.75   | 1.47%             |  |  |  | No            |                  1 | On Loan: No      |
| Aclaris Therapeutics Inc                                                   | ACLARIS THERAPEUTICS INC                          | CUSIP: 00461U105<br>LEI: 5493000B2LQ9QTW1DF52 | Long             | EC               | CORP              | US        |     89937 | NS      | $1416507.75   | 0.34%             |  |  |  | No            |                  1 | On Loan: No      |
| ELANCO ANIMAL HEALTH INCORPORATED                                          | ELANCO ANIMAL HEALTH INC                          | CUSIP: 28414H103<br>LEI: 549300SHPNDCE059M934 | Long             | EC               | CORP              | US        |    781232 | NS      | $9546655.04   | 2.28%             |  |  |  | No            |                  1 | On Loan: No      |
| REVANCE THERAPEUTICS, INC.                                                 | REVANCE THERAPEUTICS INC                          | CUSIP: 761330109<br>LEI: 549300N33TFDZHS81H11 | Long             | EC               | CORP              | US        |    144194 | NS      | $2661821.24   | 0.64%             |  |  |  | No            |                  1 | On Loan: —       |
| AMICUS THERAPEUTICS, INC.                                                  | AMICUS THERAPEUTICS INC                           | CUSIP: 03152W109<br>LEI: 549300MRD1SMUTNBPQ53 | Long             | EC               | CORP              | US        |    438225 | NS      | $5350727.25   | 1.28%             |  |  |  | No            |                  1 | On Loan: No      |
| Atea Pharmaceuticals Inc                                                   | ATEA PHARMACEUTICALS INC                          | CUSIP: 04683R106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    133145 | NS      | $640427.45    | 0.15%             |  |  |  | No            |                  1 | On Loan: No      |
| BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares | BLACKROCK CASH FUNDS INSTITUTIONAL FUND SL AGENCY | CUSIP: 066922519<br>LEI: N/A                  | Long             | STIV             | RF                | US        |  16376110 | NS      | $16381022.68  | 3.91%             |  |  |  | No            |                  1 | On Loan: No      |
| XAV HEALTH CARE MAR23                                                      | XAV HEALTH CARE MAR23                             | CUSIP: N/A<br>LEI: N/A                        | N/A              | DE               |  | US        |         4 | NC      | $1720.62      | 0.00%             |  |  |  | No            |                  1 | On Loan: No      |
| BRISTOL-MYERS SQUIBB COMPANY                                               | BRISTOL MYERS SQUIBB CO                           | CUSIP: 110122108<br>LEI: HLYYNH7UQUORYSJQCN42 | Long             | EC               | CORP              | US        |    235690 | NS      | $16957895.50  | 4.05%             |  |  |  | No            |                  1 | On Loan: No      |
| PERRIGO COMPANY PUBLIC LIMITED COMPANY                                     | PERRIGO CO PLC                                    | CUSIP: G97822103<br>LEI: 549300IFOQS6R1QLY196 | Long             | EC               | CORP              | IE        |    235972 | NS      | $8044285.48   | 1.92%             |  |  |  | No            |                  1 | On Loan: No      |
| ELI LILLY AND COMPANY                                                      | ELI LILLY CO                                      | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |    213475 | NS      | $78097694.00  | 18.64%            |  |  |  | No            |                  1 | On Loan: No      |
| JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY                                | JAZZ PHARMACEUTICALS PLC                          | CUSIP: G50871105<br>LEI: 635400GAUMJCLEZRRV50 | Long             | EC               | CORP              | IE        |    110355 | NS      | $17580655.05  | 4.20%             |  |  |  | No            |                  1 | On Loan: No      |
| ZOETIS INC.                                                                | ZOETIS INC                                        | CUSIP: 98978V103<br>LEI: 549300HD9Q1LOC9KLJ48 | Long             | EC               | CORP              | US        |    125383 | NS      | $18374878.65  | 4.39%             |  |  |  | No            |                  1 | On Loan: No      |
| JOHNSON & JOHNSON                                                          | JOHNSON JOHNSON                                   | CUSIP: 478160104<br>LEI: 549300G0CFPGEF6X2043 | Long             | EC               | CORP              | US        |    531657 | NS      | $93917209.05  | 22.42%            |  |  |  | No            |                  1 | On Loan: No      |
| INNOVIVA, INC.                                                             | INNOVIVA INC                                      | CUSIP: 45781M101<br>LEI: 549300ACOX4QTBES6535 | Long             | EC               | CORP              | US        |    110008 | NS      | $1457606.00   | 0.35%             |  |  |  | No            |                  1 | On Loan: No      |
| AXSOME THERAPEUTICS, INC.                                                  | AXSOME THERAPEUTICS INC                           | CUSIP: 05464T104<br>LEI: 549300EXGR0XLRJEIB95 | Long             | EC               | CORP              | US        |     60126 | NS      | $4637518.38   | 1.11%             |  |  |  | No            |                  1 | On Loan: —       |
| Arvinas Inc                                                                | ARVINAS INC                                       | CUSIP: 04335A105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     84892 | NS      | $2904155.32   | 0.69%             |  |  |  | No            |                  1 | On Loan: No      |
| Harmony Biosciences Holdings Inc                                           | HARMONY BIOSCIENCES HOLDINGS INC                  | CUSIP: 413197104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     51981 | NS      | $2864153.10   | 0.68%             |  |  |  | No            |                  1 | On Loan: —       |
| Nuvation Bio Inc                                                           | NUVATION BIO INC                                  | CUSIP: 67080N101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    240550 | NS      | $461856.00    | 0.11%             |  |  |  | No            |                  1 | On Loan: No      |
| ORGANON & CO.                                                              | ORGANON CO                                        | CUSIP: 68622V106<br>LEI: 549300AMCKY57OK2CO56 | Long             | EC               | CORP              | US        |    445802 | NS      | $12451249.86  | 2.97%             |  |  |  | No            |                  1 | On Loan: No      |
| PFIZER INC.                                                                | PFIZER INC                                        | CUSIP: 717081103<br>LEI: 765LHXWGK1KXCLTFYQ30 | Long             | EC               | CORP              | US        |    374975 | NS      | $19213719.00  | 4.59%             |  |  |  | No            |                  1 | On Loan: No      |
| CATALYST PHARMACEUTICALS, INC.                                             | CATALYST PHARMACEUTICALS INC                      | CUSIP: 14888U101<br>LEI: 5299004O0R5XXLA5H544 | Long             | EC               | CORP              | US        |    167804 | NS      | $3121154.40   | 0.75%             |  |  |  | No            |                  1 | On Loan: —       |
| Amylyx Pharmaceuticals Inc                                                 | AMYLYX PHARMACEUTICALS INC                        | CUSIP: 03237H101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     69673 | NS      | $2574417.35   | 0.61%             |  |  |  | No            |                  1 | On Loan: No      |
| CORCEPT THERAPEUTICS INCORPORATED                                          | CORCEPT THERAPEUTICS INC                          | CUSIP: 218352102<br>LEI: 529900EO9LUTFMZ7FF90 | Long             | EC               | CORP              | US        |    167915 | NS      | $3410353.65   | 0.81%             |  |  |  | No            |                  1 | On Loan: —       |
| AMPHASTAR PHARMACEUTICALS INC                                              | AMPHASTAR PHARMACEUTICALS INC                     | CUSIP: 03209R103<br>LEI: 54930055TH0ZLSAQMJ38 | Long             | EC               | CORP              | US        |     66070 | NS      | $1851281.40   | 0.44%             |  |  |  | No            |                  1 | On Loan: No      |
| MERCK & CO., INC.                                                          | MERCK CO INC                                      | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |    171121 | NS      | $18985874.95  | 4.53%             |  |  |  | No            |                  1 | On Loan: No      |
| PHIBRO ANIMAL HEALTH CORPORATION                                           | PHIBRO ANIMAL HEALTH CORP                         | CUSIP: 71742Q106<br>LEI: 549300U24SP4AF2JUX52 | Long             | EC               | CORP              | US        |     35728 | NS      | $479112.48    | 0.11%             |  |  |  | No            |                  1 | On Loan: No      |
| REATA PHARMACEUTICALS, INC.                                                | REATA PHARMACEUTICALS INC                         | CUSIP: 75615P103<br>LEI: 5299005F094GH9QDDD80 | Long             | EC               | CORP              | US        |     48937 | NS      | $1859116.63   | 0.44%             |  |  |  | No            |                  1 | On Loan: —       |
| Cara Therapeutics Inc                                                      | CARA THERAPEUTICS INC                             | CUSIP: 140755109<br>LEI: 549300COVOY41P0GZ881 | Long             | EC               | CORP              | US        |     79292 | NS      | $851596.08    | 0.20%             |  |  |  | No            |                  1 | On Loan: No      |
| IRONWOOD PHARMACEUTICALS, INC.                                             | IRONWOOD PHARMACEUTICALS INC                      | CUSIP: 46333X108<br>LEI: 549300PC8MR6QHH6P296 | Long             | EC               | CORP              | US        |    233893 | NS      | $2897934.27   | 0.69%             |  |  |  | No            |                  1 | On Loan: —       |
| VANDA PHARMACEUTICALS INC.                                                 | VANDA PHARMACEUTICALS INC                         | CUSIP: 921659108<br>LEI: 529900AY8VOOQBKJ0O70 | Long             | EC               | CORP              | US        |     99412 | NS      | $734654.68    | 0.18%             |  |  |  | No            |                  1 | On Loan: No      |
| Intra-Cellular Therapies Inc                                               | INTRA CELLULAR THERAPIES INC                      | CUSIP: 46116X101<br>LEI: 5299002U2KGF193IJA20 | Long             | EC               | CORP              | US        |    154363 | NS      | $8168889.96   | 1.95%             |  |  |  | No            |                  1 | On Loan: No      |
| CASSAVA SCIENCES, INC.                                                     | CASSAVA SCIENCES INC                              | CUSIP: 14817C107<br>LEI: 529900XA0UG5JXABYF08 | Long             | EC               | CORP              | US        |     66012 | NS      | $1949994.48   | 0.47%             |  |  |  | No            |                  1 | On Loan: —       |
| PRESTIGE CONSUMER HEALTHCARE INC.                                          | PRESTIGE CONSUMER HEALTH                          | CUSIP: 74112D101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     86800 | NS      | $5433680.00   | 1.30%             |  |  |  | No            |                  1 | On Loan: —       |
| THERAVANCE BIOPHARMA, INC.                                                 | THERAVANCE BIOPHARMA INC                          | CUSIP: G8807B106<br>LEI: 5493007VTSXP4Z6MIW52 | Long             | EC               | CORP              | KY        |    101225 | NS      | $1135744.50   | 0.27%             |  |  |  | No            |                  1 | On Loan: No      |
| Pliant Therapeutics Inc                                                    | PLIANT THERAPEUTICS INC                           | CUSIP: 729139105<br>LEI: 5493002Q5LITR7VHZH02 | Long             | EC               | CORP              | US        |     58882 | NS      | $1138189.06   | 0.27%             |  |  |  | No            |                  1 | On Loan: No      |
| PACIRA BIOSCIENCES, INC.                                                   | PACIRA BIOSCIENCES INC                            | CUSIP: 695127100<br>LEI: 549300P56LERYBDHCF69 | Long             | EC               | CORP              | US        |     80413 | NS      | $3104745.93   | 0.74%             |  |  |  | No            |                  1 | On Loan: —       |
| ROYALTY PHARMA PLC                                                         | ROYALTY PHARMA PLC                                | CUSIP: G7709Q104<br>LEI: 549300FGFN7VOK8BZR03 | Long             | EC               | CORP              | GB        |    447157 | NS      | $17671644.64  | 4.22%             |  |  |  | No            |                  1 | On Loan: No      |
| Dice Therapeutics Inc                                                      | DICE THERAPEUTICS INC                             | CUSIP: 23345J104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     59320 | NS      | $1850784.00   | 0.44%             |  |  |  | No            |                  1 | On Loan: No      |
| VIATRIS INC.                                                               | VIATRIS INC                                       | CUSIP: 92556V106<br>LEI: 254900ZZTSW7NL773X71 | Long             | EC               | CORP              | US        |   1728323 | NS      | $19236234.99  | 4.59%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2023-01-30

**Name of Applicant:** iShares Trust

**Signature:** Ann Frechette

**Name of Signer:** Ann Frechette

**Title:** Assistant Treasurer